EDITION IIINouvelle Formulation de l'Insuline Glargine vs Lantus® pour le Contrôle du Diabète de Type 2 chez les Patients Naïfs d'Insuline

HOE901-U300 (new formulation of insulin glargine)

Lantus (insulin glargine)

Change in HbA1c From Baseline to Month 6 Endpoint

Percentage of Participants With At Least One Severe and/or Confirmed Nocturnal Hypoglycemia From Start of Week 9 to Month 6

Change in Preinjection Self-Monitored Plasma Glucose (SMPG) From Baseline to Month 6 Endpoint

Variability of Preinjection SMPG at Month 6 Endpoint

Percentage of Participants With HbA1c <7% at Month 6

Change in Fasting Plasma Glucose (FPG) From Baseline to Month 6 Endpoint

Percentage of Participants With FPG <5.6 mmol/L (100 mg/dL) at Month 6

Change in 8-Point SMPG Profiles Per Time Point From Baseline to Month 6

Change in 24-hour Average 8-point SMPG Profile From Baseline to Month 6 Endpoint

Change in Variability of 24 Hour Average 8-point SMPG Profiles From Baseline to Month 6 Endpoint

Change in Daily Basal Insulin Dose From Baseline to Month 6

Change in Total Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint

Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline up to Month 12